Bayer AG (WAR:BAY) Cyclically Adjusted Revenue per Share: zł224.39 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:BAY Bayer AG WAR:BAY
45 GF Score
Price zł205.30
GF Value zł115.77
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bayer AG Cyclically Adjusted Revenue per Share?

Bayer AG WAR:BAY -0.77% 45 Cyclically Adjusted Revenue per Share is zł224.39 as of Mar. 2026. GuruFocus rates WAR:BAY with a GF Score™ of 45/100 and a GF Value™ of zł115.77 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bayer AG's adjusted revenue per share for the three months ended in Mar. 2026 was zł59.908. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is zł224.39 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Bayer AG's average Cyclically Adjusted Revenue Growth Rate was -2.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -0.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bayer AG was 3.90% per year. The lowest was -0.60% per year. And the median was 2.10% per year.

As of today (2026-07-19), Bayer AG's current stock price is zł205.30. Bayer AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was zł224.39. Bayer AG's Cyclically Adjusted PS Ratio of today is 0.91.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bayer AG was 2.52. The lowest was 0.35. And the median was 1.08.


Bayer AG  (WAR:BAY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bayer AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=205.30/224.39
=0.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bayer AG was 2.52. The lowest was 0.35. And the median was 1.08.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bayer AG Cyclically Adjusted Revenue per Share Related Terms


Bayer AG Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bayer AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG Cyclically Adjusted Revenue per Share Chart

Bayer AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 240.36 224.36 219.01

Bayer AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 228.08 228.09 221.89 219.01 224.39

WAR:BAY vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Bayer AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bayer AG Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bayer AG's Cyclically Adjusted PS Ratio falls into.


WAR:BAY
45GF Score
Bayer AG WAR:BAY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayer AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bayer AG's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=59.908/131.2583*131.2583
=59.908

Current CPI (Mar. 2026) = 131.2583.

Bayer AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 61.060 100.717 79.576
201609 42.565 101.017 55.308
201612 41.624 101.217 53.978
201703 45.121 101.417 58.398
201706 42.007 102.117 53.995
201709 41.021 102.717 52.419
201712 43.627 102.617 55.804
201803 48.323 102.917 61.630
201806 45.937 104.017 57.967
201809 41.871 104.718 52.483
201812 45.624 104.217 57.462
201903 53.642 104.217 67.560
201906 46.828 105.718 58.141
201909 41.850 106.018 51.814
201912 46.175 105.818 57.276
202003 54.868 105.718 68.124
202006 43.768 106.618 53.883
202009 38.730 105.818 48.041
202012 47.005 105.518 58.472
202103 56.734 107.518 69.261
202106 50.553 108.486 61.165
202109 44.483 109.435 53.354
202112 48.564 110.384 57.748
202203 62.325 113.968 71.780
202206 52.384 115.760 59.397
202209 43.178 118.818 47.699
202212 49.141 119.345 54.046
202303 59.555 122.402 63.864
202306 46.255 123.140 49.304
202309 42.668 124.195 45.095
202312 50.006 123.773 53.030
202403 57.839 125.038 60.716
202406 46.372 125.882 48.353
202409 42.768 126.198 44.483
202412 47.478 127.041 49.054
202503 57.414 127.779 58.977
202506 47.883 128.412 48.944
202509 43.830 129.255 44.509
202512 51.776 129.361 52.536
202603 59.908 131.258 59.908

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of zł224.39 mean?
Bayer AG (WAR:BAY) has a Cyclically Adjusted Revenue per Share of zł224.39 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bayer AG and its competitors.
Is Bayer AG's Cyclically Adjusted Revenue per Share too high?
Bayer AG's current Cyclically Adjusted Revenue per Share is zł224.39. Overall, Bayer AG has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Bayer AG's Cyclically Adjusted Revenue per Share of zł224.39 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bayer AG and its competitors. Bayer AG's current Cyclically Adjusted Revenue per Share is zł224.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (WAR:BAY) is currently considered Significantly Overvalued. The stock's GF Value™ is zł115.77, compared to a current price of zł205.30 — trading 77.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is zł224.39. Bayer AG's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bayer AG (WAR:BAY), the current Cyclically Adjusted Revenue per Share is zł224.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (WAR:BAY) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of zł205.30 is trading 77.3% above its estimated GF Value™ of zł115.77. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for WAR:BAY:

  • Cyclically Adjusted Revenue per Share: zł224.39
  • GF Value™: zł115.77 vs. price of zł205.30 (77.3% above fair value)
  • GF Score™: 45/100 with 6 warning signs

No single metric tells the full story. See the WAR:BAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
45GF Score

Get the complete analysis for WAR:BAY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł205.30
Price
zł115.77
GF Value